Introduction
The incidence of neuroendocrine tumors (NETs) has been steadily rising with a growing proportion of the patients diagnosed at an earlier stage possibly due to better diagnostic techniques such as computed tomography (CT) and endoscopy in addition to improved histological classification of NETs [1, 2] .
Surgical removal of the primary tumor is usually the first-line treatment for patients with locoregional stage NETs. The primary goal of surgical resection is curative, while secondary goals include symptom control and the limitation of tumor progression. The risk of recurrence after surgical resection is currently largely unknown. Due to the lack of clinical evidence, current consensus guidelines [3] [4] [5] suggest that patients be monitored with CT or magnetic resonance imaging scans for disease progression every 6-12 months after primary tumor resection without clear guidance regarding the optimal duration of surveillance. The current guidelines state that surveillance should be done for up to 10 years after surgery. Further adjuvant therapy is not recommended for the majority of patients. These guidelines are based on small, retrospective, single institution studies that have several limitations such as small size, inclusion of limited primary sites (mostly pancreatic NETs) and also referral and follow-up bias [6] [7] [8] [9] [10] . Therefore, a comprehensive population-based study of recurrence patterns in NETs is lacking. We chose the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, even though the data are largely limited to patients > 65 years, given its unique ability to provide information regarding recurrences since most other population-based registries such as SEER and NCDB only provide overall survival data. In this paper, we aim to evaluate the recurrence patterns among elderly patients with locoregional NETs after surgical resection and determine demographic and clinical factors associated with recurrent disease.
Materials and methods

Data source
We used the SEER registry data from the National Cancer Institute (NCI) linked with Medicare claims data. The SEER registries cover approximately 28% of the US population [11] . The SEER data provide information on tumor characteristics, demographic information and follow-up for vital status for persons diagnosed with cancer in the United States. The SEER staging system was used in the current study and tumors were classified as localized (defined as an invasive neoplasm confined entirely to the organ of origin), regional (defined as a neoplasm that extended beyond the limits of the organ of origin directly into surrounding organs or tissue and/or involving regional lymph nodes) or distant NET (defined as a neoplasm that spread to parts of the body remote from the primary tumor). Of note, unlike the 2010 WHO grading nomenclature which is focused on the proportion of tumor cells that are dividing, the SEER grading system relies on histologic differentiation, classifying tumors into well differentiated (grade 1), moderately differentiated (grade 2), poorly differentiated (grade 3), and undifferentiated/anaplastic (grade 4). Undifferentiated/anaplastic cancers are commonly designated as "grade 3 neuroendocrine carcinomas," [12] so we combined SEER grade 3 and 4 data as in prior reports [1, 13] . The Medicare claims data linked with the registry data provide additional information on the usage of health care resources, which allows researchers to identify treatments that patients received through International Classification of Diseases 9th Revision (ICD-9), Current Procedural Terminology (CPT), and Healthcare Common Procedure Coding System (HCPCS) codes in Medicare claims.
Study cohort
Our study cohort included 2366 elderly patients over age 65 who were diagnosed with localized or regional stage NETs between 1 January 2002 and 31 December 2011. The latest claims date available in the SEERMedicare data at the time of this research was 31 December 2013. NETs were identified by International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) codes: 8150, 8151, 8152, 8153, 8154, 8155, 8156, 8157, 8240, 8241, 8242, 8243, 8244, 8245, 8246, and 8249. As the aim of our study was to examine the development of metastases, we included only patients with localized or regional diseases at diagnosis who had only one primary cancer site and received surgical resection at the primary site. We captured the date of surgery by identifying claims indicating tumor resection based on the ICD-9 procedure codes and CPT/ HCPCS codes. We required continuous Medicare Parts A and B enrollment and no enrollment in health maintenance organizations (HMO) from one month before diagnosis until three months after diagnosis to ensure the completeness of medical claims to capture surgical resection as that is the time window for the identification of the receipt of surgical resection. We also excluded cases whose claims demonstrated the development of secondary malignancy within one month of surgery as these might have been patients with metastatic spread at diagnosis who were misclassified. A detailed flow chart illustrating the inclusion/exclusion criteria of our study cohort is in supplementary Figure S1 , available at Annals of Oncology online.
Identification of secondary malignancy (metastatic NET)
We identified the presence of metastatic/secondary malignancy by ICD-9 codes: 209. 70, 209.71, 209.72, 209.73, 209.74, 209.79, 197.7, 198.5, 198.3, 198.81, 197.5, 198.7, 198.0, 197.0, 197.2, 197.6, 198.2, 197.4, 198.5, 196.6, 196.0, 196.1, 196.2, 196.3, 196.5, 196.8, 197.1, 197.8, 198.4, 198.6, 198.82, 198.89, 199 .0, and 789.51. These codes were curated from similar manuscripts [14, 15] that validated their use to identify metastatic spread in breast, lung, colorectal and prostate cancer patients and modified to fit the typical clinical behavior of NETs. We defined patients as having metastatic disease if they had at least two claims with any of the aforementioned ICD-9 codes.
Explanatory variables
We included demographic characteristics, clinical factors, and neighborhood socioeconomic information as explanatory variables in our analyses. The demographic characteristics included in our analyses were age 
Statistical analyses
For bivariate analyses, we used Kaplan-Meier method and log-rank test to evaluate and compare the time to development of metastasis by stage, histological grade, site, and nodal status. Demographic and clinical characteristics between patients with and without development of metastasis were compared using Chi-squared tests. For multivariate analyses, we used Cox proportional hazard model to evaluate the effects of various factors on the development of metastases. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were reported for time to the development of metastases. To evaluate the impact of longer survival of women on risk of recurrence, a competing risk model [16] was employed to account for the competing risk of death. The events of interest were the development of metastases or death. Patients who lost continuous enrollment in Medicare Parts A and B or started enrollment in a HMO were considered to be censored at that time point because the medical claims may have been incomplete from then on.
All statistical analyses were conducted in SAS Enterprise Guide 6.1 (SAS Institute, Cary NC). The Institutional Review Board at The University of Texas MD Anderson Cancer Center exempted this study for approval because all patients in the database had been deidentified.
Results Table 1 provides the frequency and percentage of patients who developed metastases, were alive without observed metastases, or died without observed metastases under two timelines: 5 years and 10 years after tumor resection. The table also includes the results from chi-square test for group differences. Out of the 2366 patients, 369 (16%) developed metastatic disease within 5 years. The number rose slightly by 32 patients to 401 (17%) over the next 5 years. The number of patients who died without observed metastases rose sharply from 1053 (44%) to 1728 (73%) from 5 to 10 years.
The chi-square test results suggested that there were statistically significant differences in the development of metastases by cancer stage (P < 0.001). The percentage that developed metastases within 5 years was 31% versus 10% for patients with regional versus localized disease, respectively. Higher histological grade was also significantly associated with the development of metastases (P < 0.001). Similarly, tumor size was significantly associated with the development of metastases. The larger the tumor size, the higher the percentage of patients that developed metastases. We also found significant differences by primary tumor site. Nodal status did not show a statistically significant difference possibly due to the large proportion of patients (66%) with unknown nodal status. A lower percentage of female patients developed metastases within 5 year than male patients (14% versus 19%). The significant differences in disease progression by stage, grade and site were also confirmed by log-rank test with P-values for all three < 0.001 ( Figure 1A-C) . Table 2 provides the results from the multivariate Cox proportional hazards model. After adjusting for other factors, patients with regional stage disease were significantly more likely to develop metastases than patients with localized disease (HR ¼ 2.81, 95% CI: 2.24-3.53). Patients with histological grade 2 or grades 3 and 4 tumors were much more likely to have metastases with HRs of 2.23 (95% CI: 1.65-3.00) and 4.34 (95% CI: 3.31-5.71), respectively, compared to patients with grade 1 tumors. Tumor size larger than 2 cm was significantly associated with higher likelihood of developing metastases (HR ¼ 1.55, 95% CI: 1.07-2.25) compared to tumor size less than 1 cm. Compared to patients with primary tumor sites in the larynx, bronchus, lung, trachea, and other respiratory organs, patients with tumors in the small intestine and cecum (HR ¼ 0.61, 95% CI: 0.46-0.81), colon (HR ¼ 0.25, 95% CI: 0.14-0.46), and rectum (HR ¼ 0.51, 95% CI: 0.27-0.99) were significantly less likely to develop metastases while pancreatic NETs had a trend towards increased risk of developing metastases (HR ¼ 1.10, 95% CI: 0.74-1.65). Nodal status did not have a significant association with the development of metastases, which is again likely due to the large proportion of individuals with unknown nodal status. We also found that females were less likely to develop metastases (HR ¼ 0.65, 95% CI: 0.53-0.80). The results for the competing risk model are also presented in Table 2 . The significant association between tumor stage, grade, size, and site and metastatic disease were in line with the Cox proportional hazard model results; nodal status was still insignificant. The competing risk model also supported the difference in the risk of metastatic development between male and female patients (HR ¼ 0.68, 95% CI: 0.55-0.83).
Discussion
We found that the risk of developing metastases differed significantly by stage, grade, and tumor size as noted in prior studies. We also established the prognostic importance of primary site in the development of recurrent disease. While some previous small-scale studies have shown some of these differences [6] [7] [8] [9] [10] , the magnitude of such differences was not well-known or validated in a larger population before this study.
The steadily rising incidence of early, resectable NETs [1, 2] underscores the urgent need to have concrete, evidence-based guidelines for post-resection NET surveillance. Reflecting the lack of quality data, current National Comprehensive Cancer Network (NCCN) guidelines suggest surveillance for up to 10 years with evaluation every 6-12 months irrespective of site or grade for well-differentiated NETs with very few exceptions such as in the case of early and small rectal, gastric or appendiceal NETs that do not require long-term follow-up [3] . In sharp contrast, the current study reveals significant differences in risk of recurrence depending on site, grade and stage. Therefore, future surveillance guidelines for resected NETs could take these factors into consideration to customize the guidelines depending on the magnitude of risk to reduce unnecessary testing. We found that in our cohort of elderly patients above 65 years old, few patients were observed to develop metastatic disease after 5 years postresection. As patients may have been lost to follow-up due to either the end of the study period (31 December 2013) or ending continuous enrollment in Medicare Part A and B (or beginning HMO enrollment), we further examined subgroups of patients with complete 5 year and 10 year follow-up. We found that out of the 2366 patients, 1643 had complete 5-year follow-up and 1102 had complete 10-year follow-up. Among the 1643 patients who had complete 5-year follow-up, 369 developed metastatic disease. In comparison, among the 1102 patients who had complete 10-year follow-up, 401 developed metastatic disease. Therefore, this analysis confirms our finding that the development of metastases did not increase significantly between years 5 and 10 after surgical resection among elderly patients. Future studies could evaluate whether NET surveillance could be stopped after 5 years in elderly patients with competing comorbidities. One previous study showed that comorbidities were associated with higher risk of mortality among elderly local/regional stage NET patients with carcinoid syndrome [17] .
Another important unanswered question in the management of well-differentiated resected NETs is the role of adjuvant therapy. The design and initiation of adjuvant trials have been hampered by a lack of data regarding the optimal subgroups to be targeted, and the time to recurrence in these patients that would be necessary for power and sample size calculations is currently unclear. The current study addresses this issue to a certain extent by identifying subgroups at higher risk of recurrence: elderly patients with regional stage, higher grade tumors, and those arising in certain primary sites including the pancreas. These findings on association between stage, site, grade and risk of recurrence are in line with prior smaller-scale studies on some NETs [6] [7] [8] [9] [10] . Future studies should validate the findings from our study across age groups and primary sites to pave the way for adjuvant trials in these subgroups. Our study showed that women had a lower risk of recurrence even when competing risk of death was considered. 
Funding
This work was supported in part by Ipsen Pharma. The funder sponsored the purchase of SEER-Medicare data and provided funding for analytical support. All authors had unrestricted access to the final study data on request, were responsible for data interpretation, manuscript preparation, and the decision to submit for publication, and attest to the completeness and accuracy of the data and statistical analysis. No grant number is applicable.
Disclosure
The authors have declared no conflicts of interest. 
